Alexion Pharma to pay $8.4 billion for Synageva BioPharma



Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

Alexion Pharmaceuticals is spending about $8.4 billion - a huge premium — to buy Synageva BioPharma, a fellow rare disease treatment developer with no products on the market that booked a first-quarter loss of nearly $60 million.

Alexion will pay $115 in cash and a portion of its stock for each Synageva share. That puts the total per-share price at about $226, based on Alexion's Tuesday closing price.

That's more than double the value Synageva BioPharma Corp.'s closing price of $95.87 on Tuesday. Shares of the drugmaker are soaring in premarket trading.

Alexion Pharmaceuticals Inc. is based in Cheshire, Connecticut, and makes Soliris, which is approved to treat a rare, life-threatening blood disorder called paroxysmal nocturnal hemoglobinuria.

Synageva's lead product in development, the rare disease treatment Kanuma, is being reviewed by federal regulators.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast